Clinuvel Pharmaceuticals Limited (CLVLF) Financials
CLVLF Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 204.4 million | 16.1 million |
| Dec. 31, 2025 | 180.1 million | 13.8 million |
| June 30, 2025 | 178.7 million | 20.3 million |
| Dec. 31, 2024 | 146.8 million | 11.7 million |
CLVLF Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | 15.8 million | ? |
| Dec. 31, 2025 | 8.3 million | ? |
| June 30, 2025 | 18.2 million | 652690 |
| Dec. 31, 2024 | 8.1 million | 626938 |
CLVLF Net Income
| Date | Net Income |
|---|---|
| June 30, 2026 | 16.2 million |
| Dec. 31, 2025 | 7.0 million |
| June 30, 2025 | 14.5 million |
| Dec. 31, 2024 | 8.7 million |
CLVLF Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 174.0 million | - | 1.1 million |
| Dec. 31, 2025 | 155.6 million | 11515 | 11515 |
| June 30, 2025 | 147.4 million | 64014 | 347567 |
| Dec. 31, 2024 | 123.2 million | 203028 | 444517 |
CLVLF Shares Outstanding
CLVLF Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 1.0 million | 10.1 million | 8.4 million | - |
| Dec. 31, 2025 | 99799 | 2.3 million | 4.3 million | - |
| June 30, 2025 | 158292 | 3.0 million | 6.0 million | - |
| Dec. 31, 2024 | 35953 | 1.8 million | 8.0 million | 7.7 million |
CLVLF Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 39.4 million | 428880 |
| Dec. 31, 2025 | 24.7 million | 10.8 million |
| June 30, 2025 | 39.0 million | 12.3 million |
| Dec. 31, 2024 | 22.2 million | 1.9 million |
CLVLF
Price: $5.38
Dividend Yield: 0.61%
Forward Dividend Yield: 0.67%
Payout Ratio: 7.08%
Dividend Per Share: 0.04 USD
Earnings Per Share: 0.48 USD
P/E Ratio: 12.33
Exchange: PNK
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 297.4 million
Average Dividend Frequency: 1
Years Paying Dividends: 9
DGR3: 30.00%
DGR5: 30.00%